Danish venture capital firm Sunstone is considering whether to list its partly owned biotech company Santaris Pharma in the United States, and will probably make a decision this year, Sunstone told Reuters on Wednesday. Santaris, which was founded through a merger of two companies in 2003, develops drugs against liver cancer, head and neck cancer, and against metabolic and infectious diseases. In 2006, Sunstone was the lead investor in a 45 million euro ($62.00 million) venture investment in Santaris and is now the main owner with a 24.8 percent stake, around twice as much as the next two owners, pension fund LD and industrial foundation Novo A/S.
Help employers find you! Check out all the jobs and post your resume.
